Saturday, July 11, 2026

Drug profile · INN

dronedarone hydrochloride

dronedarone hydrochloride (DRONEDARONE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — dronedarone hydrochloride
US status
approved
Class
Route
ORAL
Patents
0
Programs
0
Data quality
0.84

Quick answer

dronedarone hydrochloride (DRONEDARONE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN dronedarone hydrochloride
Brand DRONEDARONE HYDROCHLORIDE
Mechanism Sodium channel alpha subunit blocker
Target Inward rectifier potassium channel 2
Route ORAL
Formulation TABLET

Mechanism of action

Sodium channel alpha subunit blocker

Primary target: Inward rectifier potassium channel 2

Approval history

Authority Status Date
FDA approved

Frequently asked questions

What is dronedarone hydrochloride?

dronedarone hydrochloride (DRONEDARONE HYDROCHLORIDE) is a sodium channel alpha subunit blocker. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for dronedarone hydrochloride?

DRONEDARONE HYDROCHLORIDE is a marketed brand name for dronedarone hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of dronedarone hydrochloride?

dronedarone hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.